The invention relates to racemic or enantiomerically pure 4-pyrrolidino
derivatives, processes for their preparation, pharmaceutical compositions
comprising said derivatives, and their use in the prevention and
treatment of a disease which is mediated by a monoamine oxidase B
inhibitor, in particular Alzheimer's disease and senile dementia.